Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Asset Writedowns and Impairment (2019)

Regen BioPharma (RGBP) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with $118121.0 as the latest value for Q1 2019.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $118121.0 in Q1 2019 year-over-year; TTM through Dec 2019 was $118121.0, a N/A change, with the full-year FY2019 number at $118121.0, changed N/A from a year prior.
  • Asset Writedowns and Impairment was $118121.0 for Q1 2019 at Regen BioPharma.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $118121.0 in Q1 2019 to a low of $118121.0 in Q1 2019.